Kornimate/medical-research-clean huggingface dataset:
role of lilra3 in ankylosing spondylitis and axial psoriatic patients

Conditions: Autoimmune Diseases

Summary: 1. to evaluate the frequency of lilra3 in ankylosing spondylitis and axial psoriatic arthritis patients. 2. to investigate the association of lilra3 with ankylosing spondylitis and axial psoriatic arthritis disease activity and severity.

axial spondyloarthritis (axspa) is a complex inflammatory condition that affects the axial skeleton including the sacroiliac joints and the spine (1). it also affects peripheral joints and can be associated with extra-musculoskeletal manifestations including uveitis, psoriasis, and inflammatory bowel disease (1). axial spondyloarthritis include ankylosing spondylitis (as), certain forms of psoriatic arthritis (psa), reactive arthritis with axial involvement, and arthritis associated with inflammatory bowel disease (2). the diagnosis of axspa remains very challenging with years of delays attributed to several different factors. there is also a strong need to identify new serological biomarkers that can aid clinicians for diagnosis of axspa. leucocyte immunoglobulin-like receptor a3 (lilra3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) the function of lilra3 remains obscure, but lilra3 could bind to hla class i molecules hla-g and hla- c (4) and may act as an antagonist on other lilrs or a soluble ligand to other receptors(5) growing evidence shows that (lilra3) is associated with many autoimmune disorders.(6) (7) the functional lilra3 is a susceptibility factor for as and axial psoriatic arthritis (axpsa) has not been investigated.

Eligibility criteria:
inclusion criteria:adult as and axpsa patients \<18 years who fulfilled the assessment of spondyloarthritis international society (asas) criteria for axspa. - exclusion criteria:1-patients less than 18 years old 2-individuals with other autoimmune diseases -
a study of ak109 and ak104 in advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma

Conditions: Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Summary: this is a multicentre, phase ib/ii clinical study of ak109 and ak104 with or without chemotherapy in second-line treatment of advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma .


Eligibility criteria:
inclusion criteria: 1. written and signed informed consent 2. age ≥ 18 years but ≤ 75 years 3. ecog of 0 or 1. 4. estimated life expectancy of ≥3 months. 5. histologically or cytologically documented advanced unresectable or metastatic gastric adenocarcinoma or gastroesophageal junction (gej) adenocarcinoma. 6. at least one measurable lesion per recist v1.1. 7. gastric adenocarcinoma or gastroesophageal junction (gej) adenocarcinoma with failure of first-line treatment with anti-pd-1/l1 and chemotherapy 8. adequate organ function. 9. have agreed to take effective contraception from the date of signing the informed consent form until 120 days after the last administration. exclusion criteria: 1. other invasive malignancies within 3 years, except for locally treatable (manifested as cured) malignancies, such as basal or skin squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ. 2. any previous systemic therapy targeting vegf or anti-vegfr signaling pathways. 3. in addition to pd1 or pd-l1,prior exposure to anti-ctla-4 antibody, or any other antibody or drug therapy for t cell co-stimulatory or checkpoint pathways, such as icos or agonists (e.g. cd40, cd137, gitr and ox40 etc). 4. known history of primary immunodeficiency virus infection. 5. known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. 6. known history of interstitial lung disease. 7. known history of active tuberculosis (tb). 8. central nervous system (cns) metastasis, meningeal metastasis, spinal cord compression, or leptomeningeal disease. 9. patients with untreated chronic hepatitis b or hbv dna exceeding 500iu/ml or active hepatitis c should be excluded. patients with hcv antibody positive are eligible to participate in the study if the results of hcv rna test show negative. 10. known history of testing positive for human immunodeficiency virus (hiv). 11. uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage. 12. subjects with active, known or suspected autoimmune disease, or a medical history of autoimmune disease, with the exceptions of the following: vitiligo, alopecia, grave disease, psoriasis or eczema not requiring systemic treatment within the last 2 years, hypothyroidism (caused by autoimmune thyroiditis) only requiring steady doses of hormone replacement therapy and type i diabetes only requiring steady doses of insulin replacement therapy, or completely relieved childhood asthma that requires no intervention in adulthood, or primary diseases that will not relapse unless triggered by external factors. 13. pregnant or lactating women.
repaired tetralogy of fallot: risc score from mri & clinical data to predict the need for change of treatment

Conditions: Tetralogy of Fallot; Congenital Heart Disease

Summary: patient with tetralogy of fallot need live-long surveillance after initial operative correction (rtof). mri is an established and important component of the standardized follow-up in this patient population. a new score will be used to summarize the multitude of mri-based parameters into a single number. individual modificators are assigned to the components of the score. the value of each modificatory will be determined as a result of this feasibility trial. this new compound score is designed to anticipate any deterioration of cardiac function, arrhythmias or sudden cardiac death. this feasibility study is the first step to establish this score and find initial values for the modifies that are assigned to the more than 40 biomarkers from mri, clinical examinations and serum parameters that are included in this new score.

patient with tetralogy of fallot need live-long surveillance after initial operative correction (rtof). mri is an established and important component of the standardized follow-up in this patient population. though a large number of diverse mri-derived parameter have been shown to correlate with the incidence of major adverse cardiac events in patients with rtof, there is not a single mri-derived parameter that reliably predicts the incidence of heart failure, malignant arrhythmias or sudden cardiac death - the most common major adverse cardiac events in this group (rtof-mace). this feasibility trial is set to evaluate the feasibility of a weighted compound risk score based on about 40 parameters derived from mri and augmented by clinical as well as serum-based biomarkers. this trial will recruit 70 consecutive patients with rtof and correlate the new compound score with the clinical course over 2 years and the incidence of any change in therapy due to cardiac reasons. at the end of the trial each of the contributing parameters of the compound score will have been assigned a modifier based on its statistical relevance for the prediction of patient-specific rtof-mace or any change in cardiac related therapy. based on this feasibility trial we aim to use the weighted compound score in a large multicenter trial to proof its applicability and relevance to short, medium and longterm prognosis of this special patient group.

Eligibility criteria:
inclusion criteria: * rtof; age above 16; eligible for mri-exam exclusion criteria: * any contraindications to mri; unstable patient; unresponsive patient

Keywords: mri tetralogy of fallot multiparametric score cardiac
study of capecitabine and cetuximab as first-line therapy in patients with metastatic wild type kirsten rat sarcoma viral oncogene homolog (kras) colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the combination of capecitabine and cetuximab as first-line therapy will result in improved progression free survival compared to single agent capecitabine in patients with kras wild type colorectal cancer. patients who are not able or willing to take oxaliplatin/irinotecan combination therapy are eligible for this study.


Eligibility criteria:
inclusion criteria * metastatic colorectal cancer * tumor classified wt kras * at least 18 yrs of age * ecog ps 0,1 or 2 * evidence of adequate organ function * measurable disease per recist criteria * have at least two of the following criteria: * age \> 65 years * ecog ps 1 or 2 * serum albumin \< or equal to 3.5g/dl * prior rt to abdomen or pelvis * stopped first-line combination systemic chemotherapy \< 6 weeks duration exclusion criteria * tumors classified as kras mutation * prior therapy with cetuximab, panitumumab or other agent that targets egfr * prior exposure to any biologic * known sensitivity to cetuximab or 5-fu (or marked intolerance to 5-fu) * known dpd deficiency * uncontrolled angina or a myocardial infarction within the previous 12 months * concurrent severe uncontrolled medical illness * known uncontrolled cns metastases * bowel disease associated with chronic diarrhea * major surgery within 28 days
efficacy and safety of telmisartan and losartan in primary hypertension

Conditions: Hypertension

Summary: using losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the treatment of the mild to moderate primary hypertension patients in china


Eligibility criteria:
inclusion criteria: - mild to moderate primary hypertension, the mean sitting valley value of diastolic blood pressure (dbp) ≥ 95 and \< 110 mmhg, and the mean sitting valley value of systolic blood pressure (sbp) \< 180 mmhg exclusion criteria: - not specified
safety, tolerability and efficacy of weekly tv-1106 in adults with growth hormone deficiency

Conditions: Growth Hormone Deficiency

Summary: the primary objective of this study is to evaluate the clinical effect of tv-1106.


Eligibility criteria:
inclusion criteria: * patient agrees to provide written informed consent and to comply with the study protocol after reading the informed consent and discussing the study with the investigator. * males and females between 23 and 65 years of age must have a confirmed diagnosis of adult ghd, either adult onset (ao) ghd due to hypothalamic-pituitary disease or childhood onset (co) ghd that is either idiopathic or due to hypothalamic-pituitary disease or due to genetic causes. * diagnosis of gh deficiency must be confirmed by documented (medical records) diagnostic testing. * patients should have been treated with a stable dose of daily rhgh for at least 3 months prior to screening. * other criteria apply. exclusion criteria: * patients with history or clinical evidence of active or chronic diseases that could confound results of the study or put the subject at undue risk as determined by the investigator. * patients with known active malignancy * patients with history of malignancy other than intracranial tumor causing ghd (excluding surgically cured basal cell or squamous cell cancer of the skin with documented 6 month remission) * patients with evidence of pituitary adenoma or other intracranial tumor within 12 months of enrollment, which is on day 0 (baseline, visit 3) * patients without magnetic resonance imaging (mri) or computerized tomography (ct) data to document tumor stability within the 12 months prior to enrollment, which is on day 0 (baseline, visit 3) * presence of prader-willi syndrome, turner's syndrome, untreated adrenal insufficiency, active acromegaly in the past 5 years, or active cushing's syndrome in the past 1 year. * other criteria apply.

Keywords: growth hormone deficiency insulin-like growth factor i (igf-i) tv-1106
randomized controlled crossover comparison of icon underwear to disposable pads

Conditions: Reusable Underwear, Urinary Incontinence, Dispoable Pad

Summary: this is a randomized cross over trial to compare quality of life and product performance between icon reusable underwear versus standard disposable pad in patients with mild to moderate urinary incontinence.

urinary incontinence is estimated to affect approximately 1/5 of all women in the united states. multiple studies have compared effectiveness, cost-effectiveness and comfort of a variety absorbent products but most of the current data compares daily disposable insert pads. icon reusable underwear is a new product on the market for light incontinence (25-30ml daily). the primary objective of this randomized cross over trial is to compare quality of life and patient comfort and to determine patient preference using icon reusable underwear versus standard incontinence pad in the management of urinary incontinence. the secondary objective is to compare the cost-effectiveness of icon underwear to disposable pads. women with small to moderate urinary incontinence to use either icon underwear or pads for two days and then crossed over to use other product for two days. the primary outcome measures were incontinence quality of life instrument 3 (i-qol) and product performance questionnaire 4 (ppq) after use of each product. a sample size of 70 was calculated to detect a difference of 10.0 in the i-qol to achieve a power of 80% with a significance level of 0.05 and to account for a 20% attrition.

Eligibility criteria:
inclusion criteria: * female patients who are at least 18yo * mild to moderate urinary incontinence, defined as a response "small" or "moderate" amount to the iciq-sf question - "how much do you leak?" exclusion criteria: * active urinary tract infection * fecal incontinence, defined as a response "large" amount to the iciq-sf question - "how much do you leak?"
milieu teaching-av (mt-av pilot)

Conditions: Autism Sibling; Autism Spectrum Disorder

Summary: this project will look at whether a novel approach to language intervention that encourages looking to audiovisual speech cues for infants with autistic older siblings (baby sibs), who are highly likely be diagnosed with autism or developmental language disorder (dld). this study will specifically look at (a) whether caregivers find this approach to be easy to implement in their homes, (b) whether they find this approach to be acceptable, and (c) whether caregivers use the taught strategies in interactions with their infants.

this project will test the feasibility and acceptability of a novel approach to language intervention based on milieu teaching (milieu teaching-av) that encourages looking to audiovisual speech cues for infants with autistic older siblings (sibs-autism), who are highly likely be diagnosed with autism or developmental language disorder (dld). the main question\[s\] it aims to answer are: 1. can caregivers be trained in milieu teaching-av, such that they are using the trained strategies in play with their infant children? 2. do caregivers find these procedures to be acceptable and feasible to use in their everyday life.

Eligibility criteria:
inclusion criteria: * an older sibling with an autism diagnosis, confirmed by either (a) a detailed developmental interview and administration of the autism diagnostic observation schedule or (b) by record review * monolingual english-speaking household exclusion criteria: * adverse neurological history * known genetic condition * pre-term birth (gestation \< 37 weeks) * caregiver report of a diagnosed vision impairment or hearing loss

Keywords: parent-mediated caregiver-mediated
prospective hospital registry of patients with suspected or confirmed coronavirus infection (covid-19) and community-acquired pneumonia

Conditions: COVID 19

Summary: coronavirus-2019 disease (covid-19) and community-acquired pneumonia are significant problems of modern medicine. pneumonia is the most common severe complication of covid-19. but at the same time, covid-19 is not the only cause of community-acquired pneumonia. moreover, pneumonia is only one of the numerous possible severe complications of covid-19. medical centers specialized for the hospital treatment of patients with severe covid-19 and community-acquired pneumonia were organized in different regions of russia during coronavirus pandemic-2020. the indications for hospitalization to one of these centers based in the national medical and surgical center (nmsc) are: confirmed or suspected severe covid-19 or community-acquired pneumonia. a prospective medical registry of such patients hospitalized to nmsc, is intended to analyze and compare their clinical and instrumental data, co-morbidity, treatment, short-term and long-term outcomes in real clinical practice. stage 1. hospital treatment in nmsc duration of this stage: from the date of admission to the hospital up to the date of discharge from the hospital / or up to the date of death during the reference hospitalization. the date of admission to the hospital will be the date of enrollment to the study. evaluation of electronic health record data using the medical information system (mis). assessment of the outcomes of the hospital phase (discharge from the hospital, death) and significant events (acute respiratory and pulmonary failure, requiring mechanical ventilation; cardiovascular events - myocardial infarction, cerebral stroke, acute heart failure, paroxysmal heart rhythm disturbances, bleedings, thrombosis of large vessels and thromboembolic complications). a survey of patients to clarify data on risk factors, somatic diseases, and drug therapy before hospitalization. covid-19 was diagnosed when severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection was confirmed by polymerase chain reaction (pcr). pneumonia was confirmed according to computerized tomography (ct) data. stage 2. prospective outpatient follow-up for 24 months duration of this stage: 24 months after discharge from the hospital this work will be delivered by investigators from the national medical research center for therapy and preventive medicine. evaluation of long-term outcomes and events among residents of moscow and the moscow region according to a patient survey (contact by phone for 30-60 days, 6 months, 12 and 24 months after discharge from the hospital) and medical records.


Eligibility criteria:
inclusion criteria: 1. patients hospitalized to the national medical and surgical center named after n.i.pirogov of the ministry of health of russia (nmsc) with suspected or confirmed covid-19 or community-acquired pneumonia. 2. age 18 years and older. 3. permanent residency in russia. exclusion criteria: 1. permanent residency outside of russia. 2. the patient's refusal to participate in the study.
prospective outpatient registry of myocardial infarction patients

Conditions: Myocardial Infarction

Summary: the investigators enrolled 160 patients who visited moscow state outpatient clinic №9 (and its two branches) within six months after acute myocardial infarction. the enrollment lasted from 01.03.2014 to 01.07.2015. the observation period is five years. during the first year after enrollment in the study, patients had follow-up visits every two months, from second-year every six months. analysis of the prescribed therapy and its changes was carried out by the cardiologist in the clinic for the entire observation period, taking into account the concomitant diseases /indications/contraindications. endpoints (the death, repeated cardiovascular complications (ami, stroke), emergency hospitalization due to worsening of the main cardiovascular disease, the appearance of clinically significant cardiac arrhythmias, invasive interventions) were defined during out-patient visits and telephone contact


Eligibility criteria:
inclusion criteria: * patients who have undergone ami and applied no later than 6 months. after discharge from the hospital to the moscow outpatient clinic № 9 from march 1, 2014, to december 31, 2015; * availability of discharge summary with confirmed ami; * permanent residence on the territory of moscow and the moscow region; * the signing of informed consent to the processing of personal data. exclusion criteria: * patients with the absence of discharge summary from the hospital with a proven history of ami; * visit the clinic in a period exceeding six months from the ami;

Keywords: myocardial infarction, registry
you and me healthy

Conditions: COVID-19

Summary: the you and me healthy registry provides a resource for collecting information on people currently living in the united states. the overall goal of the registry is to create and engage a community of people who may be eligible for participation in future research studies aiming to answer research questions about covid-19 and other conditions.

severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is a novel betacoronavirus responsible for the covid-19 pandemic. in the united states (us) up until january 2022, \> 60 million people have been infected with the sars-cov-2 virus and \>800,000 died, with infections and deaths disproportionally affecting populations that have been historically marginalized1. wide disparities also persist by race/ethnicity and age with covid-19 testing and vaccine uptake related to social and structural factors, resulting in adverse health consequences. as public health measures have scaled up, mitigation strategies are increasingly being considered to reduce community spread of infection. these measures include rapid-result at-home tests, protective measures (masking, social distancing, increased hygiene), treatments, and contact-tracing and isolation. as the pandemic evolves, new discoveries, technologies, and strategies to combat covid-19 are being implemented with limited backing of research data. to address this continued unmet public health need, the you and me healthy registry is being created to engage community members and serve as a way to provide and collect information from all people who are interested in engaging in upcoming research studies, including those related to covid-19.

Eligibility criteria:
inclusion criteria: * currently residing in the united states * age ≥ 2 (for minors, parents/legal guardian will be the primary point of contact) * able to speak and read in the language used in the surveys/assessments available exclusion criteria: there are no specific exclusion criteria for this registry